ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0118

Indicators of Effectiveness After 6 Years of Follow-up in a Fracture Liaison Service
Abstract Number: 2003

Individualized Prediction of Response to Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics-driven Machine Learning Approach
Abstract Number: 1010

Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
Abstract Number: 0622

Infection-induced MPO-ANCA Associated Vasculitis: A Systematic Review of Published Case Reports
Abstract Number: 0697

Inferior Tendon Structure and Function Seen in Patients with Achilles Tendinopathy and Neovascularization of the Achilles Tendon
Abstract Number: 0406

Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients
Abstract Number: 0192

Influence of Inflammatory and Non-inflammatory Rheumatic Disorders on the Clinical and Biological Profile of Adult-onset Diabetes
Abstract Number: L04

Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Abstract Number: 0634

Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
Abstract Number: 0815

Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
Abstract Number: 1843

Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids
Abstract Number: 1910

Integrated Molecular Analysis of Systemic Sclerosis Skin and Blood Highlights Significant Differences Between Major Autoantibody Subgroups
Abstract Number: 0229

Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
Abstract Number: 0437

Integrating Reproductive Health in Systemic Lupus Erythematosus in a Tertiary Care Setting
Abstract Number: 0502

Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].